Re: Wellbutrin/Depression/Claustrophia

[Schaaf Angus / Meadow Creek Ranch <sangusr@xxxxxxxx>]

Ed,
I do have personal experience with Wellbutrin. It wasnt a good one either.
After a couple of weeks, it seemed like I was on Requip again because I
startedto pass out again with Sleep Attacks like what the Requip caused with
me.I know it does work well for some though . Your article pretty well say
what is needed.
Do you have a link for the St. Louis Parkinson Newsletter. I'm always
interested in new sources of information.  Rob
----- Original Message -----
From: "Ed Grskovich" <EdGpark@xxxxxxx>
To: <PARKINSN@xxxxxxxxxxxxxxxxxxxx>
Sent: Saturday, January 19, 2002 1:57 PM
Subject: Re: Wellbutrin/Depression/Claustrophia


> Emily,
> I have no direct knowledge about Wellbutrin [bubroprion], but one very
> interesting study suggested that besides acting as an antidepressant it
might
> also help persons with early stage Parkinson's.
>
> "BOSTON, Sep 27, 2001 (United Press International via COMTEX) --
Preliminary
> laboratory studies suggest the antidepressant bubroprion may help slow the
> degenerative Parkinson's disease, but whether the approach works in humans
> remains to be seen. "
> See:    <A
>
HREF="
ar
>
> kinsons.html">Antidepressant May Slow Parkinson's</A>
> Or:
>

on
>
> s.html
>
> However, after you see the neuro and get PD meds, a warning comes into
play.
>
> See the following from the St. Louis Parkinson Newsletter:
>
> Does Wellbutrin, an antidepressant, relieve PD symptoms?
> Wellbutrin (buproprion) inhibits the reuptake of dopamine at the nerve
cell
> terminal. Thus, it can strengthen the effect of the remaining dopamine.
> That is, in the PD patient, the remaining dopamine nerve cells release
> dopamine (but not enough of it). Then Wellbutrin inhibits the nerve cell
> from taking it back out of the synapse (gap between the nerve cells) where
it
> acts. This ìreuptakeî is one of the ways its action would usually be
> stopped. So the remaining dopamine can have a ìstrongerî effect because it
> is allowed to work longer. This is not a very strong effect. If you give
> Wellbutrin alone to a PD patient, he is not usually noticeably better with
> respect to his parkinsonian symptoms. Wellbutrin also inhibits
> norepinephrine and serotonin reuptake which are probably important for its
> antidepressant effect. My chief concern is that when it is given with
> levodopa it may enhance the effect of levodopa a little but it has an even
> greater chance of enhancing the potential side effects of levodopa. I
would
> agree with the warning put out by its maker, Glaxo Wellcome, in the
Physician
> Desk Reference that ìlimited clinical data suggest a higher incidence of
> adverse events in patients receiving concurrent administration of
buproprion
> and levodopa. Administration of Wellbutrin SR tablets to patients
receiving
> levodopa concurrently should be undertaken with caution, using small doses
> and gradual dose increases.î I would also point out that Zyban, marketed
as
> an aid to help stop smoking, is the same thing as Wellbutrin. It is just
> another name for buproprion.
>
> To repeat, if the patient is also being given levodopa, Wellbutrin "may
> enhance the effect of levodopa a little but it has an even greater chance
of
> enhancing the potential side effects of levodopa."
>
> ed g
>
> ----------------------------------------------------------------------
> To sign-off Parkinsn send a message to:
mailto:listserv@xxxxxxxxxxxxxxxxxxxx
> In the body of the message put: signoff parkinsn

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn